Christopher Bull Granger
Duke University
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Atrial Fibrillation Management and Outcomes
Strong evidence · 8 supporting papers · latest 2026
Acute Myocardial Infarction Research
Strong evidence · 2 supporting papers · latest 2026
Heart Failure Treatment and Management
Solid evidence · 4 supporting papers · latest 2026
Antiplatelet Therapy and Cardiovascular Diseases
Solid evidence · 4 supporting papers · latest 2026
Blood Pressure and Hypertension Studies
Solid evidence · 1 supporting paper · latest 2026
Lipoproteins and Cardiovascular Health
Solid evidence · 1 supporting paper · latest 2026
Vitamin K Research Studies
Solid evidence · 2 supporting papers · latest 2026
Venous Thromboembolism Diagnosis and Management
Solid evidence · 2 supporting papers · latest 2026
Publications (15)
DOAC score among patients receiving Vitamin K antagonists
2026DOIPMID 42336120
Left Atrial Appendage Closure vs Anticoagulation for Stroke Prevention in Atrial Fibrillation
2026DOIPMID 42501028
Patient-Centered Evaluation of Anticoagulation in Atrial Fibrillation
2026DOIPMID 42187550
Incidence and Predictors of Extracranial Bleeding on Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation: A COMBINE-AF Analysis
2026DOIPMID 42549517
Heterogeneity of Treatment Effect of DOACs vs Warfarin in Atrial Fibrillation
2026DOIPMID 42489381
The effect of zalunfiban on high sensitivity cardiac troponin and the association with clinical outcomes in patients with STEMI
2026DOIPMID 42303064
Clinical Patterns and Appropriateness of Apixaban Dosing in Patients With Atrial Fibrillation
2026DOIPMID 42372348
Outcomes With Warfarin in Atrial Fibrillation
2026DOIPMID 42489390
Advancing in-hospital mortality prediction for acute myocardial infarction: An analysis from the American Heart Association Get With The Guidelines–Coronary Artery Disease Registry
2026DOIPMID 41990900
KARDIA-3: ZILEBESIRAN AS ADD-ON THERAPY IN ADULTS WITH HYPERTENSION AND ESTABLISHED CARDIOVASCULAR DISEASE OR HIGH CARDIOVASCULAR RISK WITH AND WITHOUT CHRONIC KIDNEY DISEASE
2026DOI
Rational and design for test 2 treat: A randomized implementation trial to improve LDL-C management after hospitalization for ASCVD
2026DOI
Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practice
2026DOIPMID 42162604
Lost to Follow‐Up in Pragmatic Trials With Remote Follow‐Up: Insights From CONNECT‐HF and TRANSFORM‐HF
2026DOIPMID 42500873
Rural-urban differences for integrated first responder and drone automated external defibrillator delivery in North Carolina
2026DOIPMID 42727843
26-A-15172-ACC PRE-HOSPITAL ZALUNFIBAN REDUCES ACUTE STENT THROMBOSIS IN PATIENTS WITH ST ELEVATION MYOCARDIAL INFARCTION. RESULTS FROM THE CELEBRATE TRIAL
2026DOI
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Duke University
Source: OpenAlex · retrieved 2026-09-29
Source: ScienceWe Extractor · retrieved 2026-09-27